公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2010 | A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients | Yang T.-S.; Lu S.-N.; Chao Y.; Sheen I.-S.; Lin C.-C.; Wang T.-E.; Chen S.-C.; Wang J.-H.; Liao L.-Y.; Thomson J.A.; Wang-Peng J.; PEI-JER CHEN ; Chen L.-T. | British Journal of Cancer | 134 | 124 | |
2013 | Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia | Chen D.-S.; Locarnini S.; Wait S.; Bae S.-H.; PEI-JER CHEN ; Fung J.Y.Y.; Kim H.S.; Lu S.-N.; Sung J.; Tanaka J.; Wakita T.; Ward J.; Wallace J. | Journal of Hepatology | 22 | 23 | |
2006 | Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA Level | Chen C.-J.; Yang H.-I.; Su J.; Jen C.-L.; You S.-L.; Lu S.-N.; GUAN-TARN HUANG ; Iloeje U.-H.; REVEAL-HBV Study Group | Journal of the American Medical Association | 2634 | 2370 | |
2020 | Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B | Huang Y.-W.; Hsu C.-W.; Lu S.-N.; Yu M.-L.; Su C.-W.; Su W.-W.; Chien R.-N.; Hsu C.-S.; SHIH-JER HSU ; Lai H.-C.; Qin A.; Tseng K.-C.; PEI-JER CHEN | Hepatology International | 18 | 14 | |
2021 | Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy | Lin H.-H.; SHIH-JER HSU ; Lu S.-N.; Chuang W.-L.; Hsu C.-W.; Chien R.-N.; Yang S.-S.; Su W.-W.; Wu J.-C.; Lee T.-H.; Peng C.-Y.; Tseng K.-C.; Qin A.; Huang Y.-W.; PEI-JER CHEN | JGH Open | 12 | 12 | |
2020 | Secular Trends and Geographic Maps of Hepatitis C Virus Infection among 4 Million Blood Donors in Taiwan from 1999 to 2017 | Chen Y.-Y.; CHI-LING CHEN ; Chen J.-W.; Hsu N.-T.; Wei S.-T.; Hou S.-M.; Lu S.-N.; PEI-JER CHEN | Hepatology Communications | 12 | 11 | |
2006 | Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan | Lu S.-N.; Su W.-W.; Yang S.-S.; Chang T.-T.; Cheng K.-S.; Wu J.-C.; Lin H.H.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; JIN-CHUAN SHEU ; DING-SHINN CHEN ; CHIEN-HUNG CHEN | International Journal of Cancer | 120 | 111 | |
2014 | Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma | Liu J.; Yang H.-I.; Lee M.-H.; Lu S.-N.; Jen C.-L.; Batrla-Utermann R.; Wang L.-Y.; You S.-L.; CHUHSING KATE HSIAO ; PEI-JER CHEN ; Chen C.-J.; R.E.V.E.A.L.-HBV Study Group; (CHYI-FENG JAN) | Gut | 144 | 125 | |
2019 | Taiwan consensus statement on the management of chronic hepatitis B | Chien R.-N.; JIA-HORNG KAO ; Peng C.-Y.; Chen C.-H.; CHUN-JEN LIU ; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; YEN-HSUAN NI ; Chuang W.-L.; Lee C.-M.; Wu J.-C.; PEI-JER CHEN ; Liaw Y.-F. | Journal of the Formosan Medical Association | 56 | 47 | |
2002 | Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan | Chen, Tony Hsiu Hsi ; Chen C.-J.; Yen M.-F.; Lu S.-N.; Sun C.-A.; GUAN-TARN HUANG ; PEI-MING YANG ; Lee, Hsuan-Shu ; Duffy S.W. | International Journal of Cancer | 142 | 129 |